ClinicalTrials.gg
CompletedNCT00836914Updated Oct 23, 2018

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

A Phase 1 interventional study of CAL-101 and Placebo in Allergic Rhinitis, sponsored by Gilead Sciences. Completed at 1 site in Austria. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Rhinitis, Allergic with a site in Austria — 1 open to participants now, 2 under way, none of them phase 3. Rhinitis, Allergic · Austria.

Enrollment
12th of 16
41 · median 54
Started
2009
the only one that year
Phase 1
2 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
2 of 18
Gilead Sciences

Among the 18 studies in Rhinitis, Allergic with a site in Austria, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 1, and was the 4th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

1 of the 18 studies in Rhinitis, Allergic with a site in Austria is open now. Recruiting first, the newest first:

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Rhinitis, Allergic with a site in Austria, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effect of CAL-101 in subjects with allergic rhinitis.

Read the detailed description

A Phase I, randomized, double-blind crossover study of CAL-101, an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, in patients with allergic rhinitis.

03

Conditions studied

  • Allergic Rhinitis

Keywords

  • Allergic Rhinitis
  • Allergy
  • Phosphatidylinositol 3-kinase
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > or = 18 and \< or = 55 years
  2. Has a history of seasonal allergic rhinitis for at least 2 years
  3. Has sensitivity to grass pollen demonstrated by a positive response to skin prick testing
  4. Has a positive Radio Allergen Sorbent Test (> or = class 2) for grass pollen during the previous 12 months or at screening
  5. Is otherwise healthy, that is, free from illness or disease as determined by medical history, physical examination and laboratory tests, including a normal 12-lead (ECG)
  6. Has no conditions which would make the subject unlikely to be able to remain in the allergen challenge chamber for 4 hours
  7. Is available to complete all study procedures
  8. Is able to provide written , including compliance with the requirements and restrictions listed in the consent form

Exclusion criteria

Exclusion Criteria:

  1. Is a female of (non-childbearing potential means documented surgery resulting in infertility or with no menses for at least 1 year)
  2. History of chronic nasal or upper respiratory tract symptoms or disorders other than allergic rhinitis
  3. History of nonallergic rhinitis, chronic sinusitis or severe asthma
  4. Has a nasal condition likely to affect the outcome of the study, i.e. nasal septal perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal diseases
  5. Is currently taking regular medication, whether prescribed or not, including , vitamins, macrolides, anti-fungal agents and herbal remedies, e.g. St. John's Wort. Paracetamol (\< or = 2g/day) and as needed use of short-acting B2-agonists are allowed.
  6. Has taken a prohibited medication within the specified interval prior to Visit 1:

    • Corticosteroids (depot, 90 days; systemic, 30 days; dermatologic 14 days)
    • Chromones (14 days)
    • Antihistamines (nasal and long-acting oral, 10 days; shorting-acting oral, 2 days; ocular, 3 days)
    • Decongestants (3 days)
    • Leukotriene modifiers (10 days)
    • Anticholinergics (7 days)
    • Opthalmic nonsteroidal
    • anti-inflammatory drugs (3 days)
    • Nasal-ophthalmic wash solutions (12 hr)
    • Immunotherapy (12 hr)
  7. Is currently being treated with a medication that induces or inhibits cytochrome P450 (CYP)3A
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    CAL-101

    Drug: CAL-101

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • CAL-101 100mg capsules administered orally twice a day (BID) for 7 days

    Also known as: Idelalisib, GS-1101

  • DrugPlacebo

    Placebo capsules administered orally BID for 7 days

06

What researchers measure

Primary outcomes

  1. Evaluate the safety CAL-101 using adverse events, vital signs, clinical laboratory tests, spirometry and ECG

    Time frame: Baseline to Day 35

Secondary outcomes

  1. Change from baseline in total nasal symptom score

    Time frame: Baseline to Day 35

07

Study locations

1 site
  • Vienna Challenge Chamber
    Vienna, Austria
08

References and documents

Publications

  • Horak F, Puri KD, Steiner BH, Holes L, Xing G, Zieglmayer P, Zieglmayer R, Lemell P, Yu A. Randomized phase 1 study of the phosphatidylinositol 3-kinase delta inhibitor idelalisib in patients with allergic rhinitis. J Allergy Clin Immunol. 2016 Jun;137(6):1733-1741. doi: 10.1016/j.jaci.2015.12.1313. Epub 2016 Feb 23. PubMed 26915677 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 4, 2009
Start
Feb 2009
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00836914
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 4, 2009
Start date
Feb 2009
Primary completion
Mar 2009
Completion
Mar 2009
Last update
Oct 23, 2018

Study contacts

Friedrich Horak, MD
principal investigator · Vienna Challenge Chamber

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion